Author's response to reviews

Title: Enhancing quality and integrity in biomedical research in Africa: An international call for greater focus, investment and standardisation in capacity strengthening for frontline staff

Authors:

Francis Kombe (Fkombe@kemri-wellcome.org)

Version: 3 Date: 29 May 2015

Author's response to reviews: see over
Dear Editorial Team

The article is a commentary which emanates from an international workshop on frontline staff who work in medical health research field. The authors believe that this type of article wouldn’t necessarily require an abstract in the proposed structure. We all the same managed to develop a short abstract which we believe meets the stated structure.
Please revise your manuscript to include line and page numbers. Authors are asked to ensure that line numbering is included in the main text file of their manuscript at the time of submission to facilitate peer-review. Once a manuscript has been accepted, line numbering should be removed from the manuscript before publication. For authors submitting their manuscript in Microsoft Word please do not insert page breaks in your manuscript to ensure page numbering is consistent between your text file and the PDF generated from your submission and used in the review process.

**This has been done**

4.) Manuscript Section

*Methods*

The methods section should include the design of the study, the setting, the type of participants or materials involved, a clear description of all interventions and comparisons, and the type of analysis used, including a power calculation if appropriate. Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.

For studies involving human participants a statement detailing ethical approval and consent should be included in the methods section. For further details of the journal's editorial policies and ethical guidelines see 'About this journal'.

For further details of the journal's data-release policy, see the policy section in 'About this journal'.

*Results and discussion*

The Results and discussion may be combined into a single section or presented separately. Results of statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The Results and discussion sections may also be broken into subsections with short, informative headings.

**All the above comments have been done**

5.) Ethics

Please note that all submissions to BMC Medical Ethics must comply with our editorial policies. In particular, please ensure that your manuscript contains any required statements regarding ethical approval and consent from patients/participants; adheres to any relevant standards of reporting with a completed checklist where appropriate; and contains an Availability of Supporting Data section explaining how the supporting data is available to researchers, including the repository and accession number where appropriate. Manuscripts which do not adhere to our
editorial policies may experience delays or be rejected. Further information about our editorial policies can be found at the following links:

Ethical approval and consent: http://www.biomedcentral.com/about/editorialpolicies#Ethics
Standards of reporting:http://www.biomedcentral.com/about/editorialpolicies#StandardsofReporting
Data availability: http://www.biomedcentral.com/about/editorialpolicies#DataandMaterialRelease.

This has been done

6.) List of abbreviations

If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.

This has been done

7.) Competing interest

Please be advised that manuscripts must include a ‘Competing interests’ section. This should be placed after the Conclusions/Abbreviations. If there are none to declare, please include the statement “The authors declare that they have no competing interests.” Please consider the following questions and include an appropriate declaration of competing interests in your manuscript:

Financial competing interests
• In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
• Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
• Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
• Do you have any other financial competing interests? If so, please specify.

Non-financial competing interests
• Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
For more information please visit the instructions for authors on the journal’s website.

All the above comments have been done

8.) Author's Contribution

For manuscripts with more than one author, all BMC Series journals require an Authors' Contributions section to be placed after the Competing Interests section. An 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.

We suggest the following format (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support.

This has been done

9.) Acknowledgements

By way of a section ‘Acknowledgements’, please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.

The role of a scientific (medical) writer must be included in the acknowledgements section, including their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section.

**This has been done**

10.) Figure legends

The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words.

**This was not applicable. The article does not contain any figures**

We do hope that you will favorably consider publishing this article.

Yours faithfully,

Francis Kombe
Corresponding author